April 1, 2020 -- The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31.
As part of Danaher, the business will be called Cytiva and will operate as a standalone company within Danaher's Life Sciences segment.
The deal, which was originally announced in February 2019, was completed with a cash consideration of around $20 billion to GE as well as Danaher's assumption of certain pension liabilities.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
